Treatment of infantile Pompe disease with alglucosidase alpha: The UK experience

Journal of Inherited Metabolic Disease

Volumn 33, Issue 6, 2010, Pages 747-750

  Chakrapani, Anupam ^a   Vellodi, Ashok ^b   Robinson, Peter ^c   Jones, Simon ^d   Wraith, J E ^d  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE; ALPHA GLUCOSIDASE;

ARTICLE; CHILD; CHILD DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DELAYED DIAGNOSIS; ENDOTRACHEAL INTUBATION; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE AVAILABILITY; HUMAN; INFANT; INFANT DISEASE; LONG TERM CARE; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT DURATION; TREATMENT FAILURE; UNITED KINGDOM; EVALUATION; FEEDING BEHAVIOR; FEMALE; FOLLOW UP; INFORMATION PROCESSING; MALE; MORTALITY; NEWBORN; PHYSIOLOGY; QUESTIONNAIRE; STATISTICS; TREATMENT OUTCOME;

ALPHA-GLUCOSIDASES; CHILD, PRESCHOOL; DATA COLLECTION; ENZYME REPLACEMENT THERAPY; FEEDING BEHAVIOR; FEMALE; FOLLOW-UP STUDIES; GLYCOGEN STORAGE DISEASE TYPE II; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 79952562144     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9206-3     Document Type: Article

References (7)

1. http://www.ncg.nhs.uk/?dl-id=77
2. Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D (2006) A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 148:671-676
3. Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N et al (2007) Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease. Neurology 68:99-109 (Pubitemid 46071892)
4. Kishnani PS, Corzo D, Leslie N, Gruskin D, van der Ploeg A, Clancy JP, Parini R et al (2009) Pediatr Res 66:329-335
5. Kishnani PS, Goldenburg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D et al (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26-33
6. Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11:210-219
7. van den Hout HMP, Hop W, van Digglen OP, Smeitink JAM, Smit GPA, Poll-The BT, Bakker HD et al (2003) The natural course of infantile Pompe disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332-340 (Pubitemid 36951395)